• Cresco Labs registered certain state-licensed medical cannabis facilities with the DEA following federal rescheduling of medical cannabis to Schedule III.
• Registrations cover dispensary, cultivation, and processing operations serving medical cannabis patients across the company’s footprint.
• The move uses an expedited 60-day DEA registration pathway created under the Schedule III framework.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cresco Labs Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260527517483) on May 27, 2026, and is solely responsible for the information contained therein.